# COVID-19 Provider Update

Wednesday, July 6, 2022

# Discontinuation of Monthly Calls

**Monthly CoVP calls will no longer be conducted. Calls will be scheduled as needed for relevant updates.**

**Please continue to monitor your communications for up-to-date information.**

# COVID-19 Updates

- On June 18th, CDC recommended to expand COVID-19 vaccination to children younger than 5 years of age. This decision now universally recommends COVID-19 vaccination for everyone 6 months and older. Kids under 5 can get either the Pfizer-BioNTech (3 dose) or Moderna (2 dose) primary vaccine series.

- On June 23rd, CDC recommended to expand the use of Moderna COVID-19 vaccines to include children ages 6 through 17 years. A (2 dose) series is recommended for this age group.

- June 28th, FDA's VRPBAC met to discuss COVID strain selection/future boosters.
  - Committee voted 19-2 in favor of including a SARS-CoV-2 omicron component in COVID-19 vaccines that would be used for boosters in the U.S.
  - FDA has advised manufacturers seeking to update their COVID-19 vaccines to develop modified vaccines that add an omicron BA.4/5 spike protein component to the current vaccine composition to create a two component (bivalent) booster vaccine, so that the modified vaccines can potentially be used starting in early to mid-fall 2022 (tentatively in October).

- Novavax Update

# Interim Clinical Considerations Update for Pediatric COVID-19 Vaccines

# Moderna Pediatric Schedule: People Who Are NOT Moderately or Severely Immunocompromised

| | | | |
|---|---|---|---|
| **Moderna** (6 months–5 years) | **Dose 1** (primary) | **4-8 weeks** → **Dose 2** (primary) |  0.25 mL (25 mcg) |
| **Moderna** (6–11 years) | **Dose 1** (primary) | **4-8 weeks** → **Dose 2** (primary) |  0.50 mL (50 mcg) |
| **Moderna** (12–17 years) | **Dose 1** (primary) | **4-8 weeks** → **Dose 2** (primary) |  0.50 mL (100 mcg) |

# Pfizer-BioNTech Pediatric Schedule: People Who Are NOT Moderately or Severely Immunocompromised

| | | | | | | | |
|---|---|---|---|---|---|---|---|
| **Pfizer-BioNTech** (6 months–4 years) | **Dose 1** (primary) | **3-8 weeks** | **Dose 2** (primary) | **At least 8 weeks** | **Dose 3** (primary) |  | 0.2 mL (3 mcg) |
| **Pfizer-BioNTech** (5–11 years) | **Dose 1** (primary) | **3-8 weeks** | **Dose 2** (primary) | **At least 5 months** | **Dose 3** (booster) |  | 0.2 mL (10 mcg) |
| **Pfizer-BioNTech** (12–17 years) | **Dose 1** (primary) | **3-8 weeks** | **Dose 2** (primary) | **At least 5 months** | **Dose 3** (booster) |  | 0.3 mL (30 mcg) |

# Moderna Pediatric Schedule: People Who ARE Moderately or Severely Immunocompromised

| | | | | |
|---|---|---|---|---|
| **Moderna** (6 months–5 years) | **Dose 1** (primary) | **4 weeks** → | **Dose 2** (primary) | **At least 4 weeks** → **Dose 3** (primary) |  0.25 mL (25 mcg) |
| **Moderna** (6–11 years) | **Dose 1** (primary) | **4 weeks** → | **Dose 2** (primary) | **At least 4 weeks** → **Dose 3** (primary) |  0.50 mL (50 mcg) |
| **Moderna** (12–17 years) | **Dose 1** (primary) | **4 weeks** → | **Dose 2** (primary) | **At least 4 weeks** → **Dose 3** (primary) |  0.50 mL (100 mcg) |

# Pfizer-BioNTech Pediatric Schedule: People Who ARE Moderately or Severely Immunocompromised

**Pfizer-BioNTech** (6 months–4 years)

Dose 1 (primary) → 3 weeks → Dose 2 (primary) → At least 8 weeks → Dose 3 (primary)

0.2 mL (3 mcg)

**Pfizer-BioNTech** (5 years–11 years)

Dose 1 (primary) → 3 weeks → Dose 2 (primary) → At least 4 weeks → Dose 3 (primary) → At least 3 months → Dose 4 (booster)

0.2 mL (10 mcg)

**Pfizer-BioNTech** (12 years–17 years)

Dose 1 (primary) → 3 weeks → Dose 2 (primary) → At least 4 weeks → Dose 3 (primary) → At least 3 months → Dose 4 (booster) → At least 4 months → Dose 5 (2nd booster)

0.3 mL (30 mcg)

# Schedule Resources

- At-a-glance schedule: https://www.cdc.gov/vaccines/covid-19/downloads/COVID-19-vacc-schedule-at-a-glance-508.pdf

- Interim COVID-19 immunization schedule: https://www.cdc.gov/vaccines/covid-19/downloads/COVID-19-immunization-schedule-ages-6months-older.pdf



AT-A-GLANCE

COVID-19 Vaccination Schedules

Use the schedules below to determine how many total COVID-19 vaccine doses are recommended based on primary series product, age, and immune status. This schedule does not include clinical details necessary for administering COVID-19 vaccines. For clinical details, see the resources at the end of this document.

COVID-19 Vaccination Schedule for Most People

of COVID-19 vaccine doses

DOSE 3 (primary)

†2nd booster dose for some groups

DOSE 3 (booster*)

In at least 4 months

DOSE 4 (2nd mRNA booster)†

People ages 50 years and older should get a 2nd booster.

DOSE 3 (booster*)

In at least 4 months

DOSE 4 (2nd mRNA booster)†

People ages 50 years and older should get a 2nd booster.

In at least 4 months

DOSE 3 (2nd mRNA booster)†

People ages 50 years and older should get a 2nd booster.

People ages 18 years and older who received 2 Janssen doses may get a 2nd booster.

COVID-19 Vaccine

Interim COVID-19 Immunization Schedule for 6 Months of Age and Older

CDC

The table below provides guidance for COVID-19 vaccination schedules based on age and medical condition. Scheduling considerations include:

- Administer the appropriate vaccine product based on the recipient's age and the product's age indications.
- COVID-19 vaccines may be administered on the same day as other vaccines.
- Doses administered at any time after the intervals outlined below are valid.

Detailed information can be found in CDC's Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States, see: www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html

Table 1. Immunization Schedule for Children 6 Months through 17 Years of Age

| Type | Product* | Recipient Age | For Most People | | Those Who ARE Moderately or Severely Immunocompromised | |
|---|---|---|---|---|---|---|
| | | | Doses | Interval Between Doses†‡ | Doses | Interval Between Doses†‡ |
| mRNA vaccine | Moderna (Blue vial cap with magenta-bordered label) | 6 months through 5 years | Total doses: 2 doses | | Total doses: 3 doses | |
| | | | Dose 1 to 2 | At least 4–8 weeks‡ | Dose 1 to 2 | At least 4 weeks |
| | | | | | Dose 2 to 3 | At least 4 weeks |
| | Pfizer-BioNTech (Maroon vial cap with maroon-bordered label) | 6 months through 4 years | Total number: 3 doses | | Total number: 3 doses | |
| | | | Dose 1 to 2 | At least 3–8 weeks‡ | Dose 1 to 2 | At least 3 weeks |
| | | | Doses 2 and 3 | At least 8 weeks | Dose 2 to 3 | At least 8 weeks |
| | Pfizer-BioNTech (Orange vial cap with orange-bordered label) | 5 through 11 years | Total number: 3 doses | | Total number: 4 doses | |
| | | | Dose 1 to 2 | At least 3–8 weeks‡ | Dose 1 to 2 | At least 3 weeks |
| | | | Dose 2 to 3 | At least 5 months | Dose 2 to 3 | At least 4 weeks |
| | | | | | Dose 3 to 4 | At least 3 months |
| | Pfizer-BioNTech (Purple vial cap with a purple-bordered label or gray vial cap with gray-bordered label) | 12 years through 17 years | Total number: 3 doses | | Total number: 5 doses | |
| | | | Dose 1 to 2 | At least 3–8 weeks‡ | Dose 1 to 2 | At least 3 weeks |
| | | | Dose 2 to 3 | At least 5 months | Dose 2 to 3 | At least 4 weeks |
| | | | | | Dose 3 to 4 | At least 3 months |
| | | | | | Dose 4 to 5 | At least 4 months |

* Complete the primary series with same product. If the vaccine product previously administered cannot be determined or is no longer available, any age-appropriate mRNA COVID-19 vaccine product may be administered at least 28 days after the first dose. Any COVID-19 vaccine product (age-appropriate) may be administered for a booster dose. It does not need to be the same product used for the primary series.

† Persons with a recent SARS-CoV-2 infection may consider delaying a primary series or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic).

‡ Some studies in adolescents and adults have shown the small risk of myocarditis associated with mRNA COVID-19 vaccines might be reduced and peak antibody responses and vaccine effectiveness may be increased with an interval longer than 4 weeks. An 8-week interval may be optimal for people who are not moderately or severely immunocompromised and ages 5–64 years, especially for males ages 12–39 years.

06/17/2022

1

# Pfizer-BioNTech COVID-19 Vaccine Products

| |  Product for ages 6 mons – 4 years |  Product for ages 5–11 years |  Product for ages 12 years and older |
|---|---|---|---|
| **Authorized for ages** | 6 months–4 years | 5–11 years | 12 years and older |
| **Vial cap color** | Maroon | Orange | Gray |
| **Dose (mRNA concentration)** | 3 mcg | 10 mcg | 30 mcg |
| **Injection volume** | 0.2 mL | 0.2 mL | 0.3 mL |
| **Dilution required** | Yes—2.2 mL | Yes—1.3 mL | No |
| **Doses per vial** | 10 (after dilution) | 10 (after dilution) | 6 |

# Pfizer-BioNTech COVID-19 Vaccine Product for Ages 6 Months–4 Years

Vaccine may be discarded **12 hours** after dilution rather than **6 hours**.




Vial label states Age 2y to <5y but can be used in children ages 6 months–4 years.

# Moderna COVID-19 Vaccine Products

| Authorized Age group |  **6 months–5 years** (primary series) |  • **6–11 years** (primary series)<br>• **18 years and older** (booster doses) |  • **12 years and older** (primary series)<br>• **18 years and older** (booster doses) |
|---|---|---|---|
| **Vial cap color** | Dark blue | Dark blue | Red |
| **Label border color** | Magenta | Purple | Light blue |
| **Dose (mRNA concentration)** | 25 mcg | 50 mcg | 100 mcg (primary, age 12+); 50mcg (booster, age 18+) |
| **Injection volume volume** | 0.25 mL | 0.5 mL | 0.5 mL (primary, age 12+); 0.25mL (booster, age 18+) |
| **Dilution required** | No | No | No |
| **Doses per vial** | 10 | 5 | Maximum of 11 |

# Moderna COVID-19 Vaccine Product for Ages 6–11 Years




Labeled for "**BOOSTER DOSES ONLY**" but is authorized for:

- Primary doses in children ages 6–11 years
- Booster doses in adults ages 18 years and older

# Product Resources

- Storage, handling, preparation, and administration job aids by product: https://www.cdc.gov/vaccines/covid-19/info-by-product/index.html
- Pfizer-BioNTech label infographic: https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/infant-label-info.pdf
- Moderna label infographic: https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/Moderna-children-updated-label-iinfo-508.pdf
- At-a-glance job aids
  - Pfizer-BioNTech: https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/downloads/vaccine-at-a-glance.pdf
  - Moderna: https://www.cdc.gov/vaccines/covid-19/info-by-product/moderna/downloads/vaccine-at-a-glance.pdf



Pfizer-BioNTech COVID-19 Vaccine Products At-A-Glance
Maroon cap: 6 Months through 4 Years of Age
Orange cap: 5 through 11 years of age
Gray or Purple cap: 12 years of age and older

The tables below summarize basic storage, preparation, scheduling, administration, and dosage for Pfizer-BioNTech COVID-19 Vaccine. Use this table in conjunction with materials below:

EUA Fact Sheet
www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/comirnaty-and-pfizer-biontech-covid-19-vaccine

CDC Interim Clinical Considerations
www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html

CDC Clinical Materials
www.cdc.gov/vaccines/covid-19/info-by-product/pfizer

Interim COVID-19 Vaccination Schedule
www.cdc.gov/vaccines/covid-19/downloads/COVID-19-immunization-schedule-ages-5yrs-older.pdf

Moderna COVID-19 Vaccine At-A-Glance
Ages 6 months and older

The tables below summarize basic storage, preparation, scheduling, administration, and dosage for Moderna COVID-19 Vaccine.

EUA Fact Sheet
www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/spikevax-and-moderna-covid-19-vaccine

CDC Interim Clinical Considerations
www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html

CDC Clinical Materials
www.cdc.gov/vaccines/covid-19/info-by-product/moderna

Interim COVID-19 Vaccination Schedule
https://www.cdc.gov/vaccines/covid-19/downloads/COVID-19-immunization-schedule-ages-6months-older.pdf

Storage and Handling Basics

NOTE: Find additional guidance on storing the vaccine properly at:

- CDC's COVID-19 Clinical materials for Moderna COVID-19 Vaccine: www.cdc.gov/vaccines/covid-19/info-by-product/moderna/storage.html
- CDC's *Storage and Handling Toolkit*: www.cdc.gov/vaccines/hcp/admin/storage/toolkit/storage-handling-toolkit.pdf

| Vial cap color | Blue vial cap with magenta bordered label | Blue vial cap with purple-bordered label | Red vial cap with blue bordered label |
|---|---|---|---|
| Ages | 6 months through 5 years | 6 years through 11 years | 12 years and older |
| Supplied in multidose vial | 10 doses per vial | 5 doses per vial | Per vial:<br>▪ 10 primary doses (0.5 mL) or<br>▪ 20 booster doses (0.25 mL)<br>▪ 20 doses: Combination of primary series and booster doses<br>Discard vial and any remaining vaccine after 20 punctures. |
| Storage Temperature: Before Puncture | Between:<br>-50°C and -15°C (-58°F and 5°F) until the expiration date<br>2°C and 8°C (36°F and 46°F) for up to 30 days<br>8°C and 25°C (46° and 77°F) for a total of 24 hours. Discard vial and unused vaccine after 24 hours. | | |
| Thawing Frozen Vaccine<br>Do NOT refreeze thawed vaccine. | Between:<br>2°C and 8°C (36°F and 46°F) for 2 hours. Let each vial stand at room temperature for 15 minutes before administering.<br>OR<br>15°C and 25°C (46°F and 77°F) for 45 minutes. | | |
| Storage Temperature: After Puncture | Between:<br>2°C and 25°C (36°F and 77°F) for up to 12 hours.<br>Discard vial and any unused vaccine after 12 hours. | | |

06/24/2022

# Vaccine Dosage: CDC's Recommendation

- **CDC'S recommendation**: Children should receive the age-appropriate vaccine product and follow the schedule based on their age **on the day of vaccination**, regardless of their size or weight.
- If a person moves from a younger age group to an older age group during the primary series or between the primary series and receipt of the booster dose(s), they should receive the vaccine dosage for the older age group for all subsequent doses.
- FDA authorization allows for dosing options for certain age transitions. If these options occur, they are not considered errors and the doses "count".

# FDA allowance for Moderna age 5 to 6 years

Children who will turn from age 5 years to 6 years between doses in the primary series to receive, for any primary dose: (1) the Moderna COVID-19 Vaccine product authorized for children ages 6 months–5 years or (2) the Moderna COVID-19 Vaccine product authorized for children ages 6–11 years.




**Dose 1 (Age 5):**
0.25 mL (25 mcg) of the product for ages 6 months–5 years or
0.50 mL (50 mcg) of the product for ages 6–11 years

**Dose 2 (Age 6):**
0.25 mL (25 mcg) of the product for ages 6 months–5 years or
0.50 mL (50 mcg) of the product for ages 6–11 years

# FDA allowance for Moderna age 11 to 12 years

Children who will turn from age 11 years to 12 years between doses in the primary series to receive, for any primary dose: (1) the Moderna COVID-19 Vaccine product authorized for children ages 6–11 years or (2) the Moderna COVID-19 Vaccine product authorized for people ages 12 years and older.




**Dose 1 (Age 11):**

0.50 mL (50 mcg) of the product for ages 6–11 years

0.50 mL (100mcg) of the product for ages 12 years and older

**Dose 2 (Age 12):**

0.50 mL (50 mcg) of the product for ages 6–11 years

0.50 mL (100mcg) of the product for ages 12 years and older

# FDA allowance for Pfizer-BioNTech age 4 to 5 years

**Scenario 1**: A 2-dose primary series using the product for people ages 5–11 years (orange cap)




**Dose 1 (Age 4):**
0.2 mL (10 mcg) of the product for ages 5–11 years

**Dose 2 (Age 5):**
0.2 mL (10 mcg) of the product for ages 5–11 years

# FDA allowance for Pfizer-BioNTech age 4 to 5 years

**Scenario 2**: A 3-dose primary series initiated with the product for ages 6 months–4 years. Dose 2 and 3 may be with: the product for ages 6 months–4 years or the product for ages 5–11 years.




**Dose 1 (Age 4):**
0.2 mL (3 mcg) of the product for ages 6 months–4 years

**Dose 2 (Age 4 or 5):**
0.2 mL (3 mcg) of the product for ages 6 months–4 years, or
0.2 mL (10 mcg) of the product for ages 5–11 years

**Dose 3 (Age 5):**
0.2 mL (3 mcg) of the product for ages 6 months–4 years, or
0.2 mL (10 mcg) of the product for ages 5–11 years

# Aging up Resources

- Moderna: https://www.cdc.gov/vaccines/covid-19/downloads/Moderna-Child-Age-Transition-508.pdf

- Pfizer-BioNTech: https://www.cdc.gov/vaccines/covid-19/downloads/Pfizer-Child-Age-Transition-508.pdf



Pfizer-BioNTech COVID-19 Vaccine
for Children who Transition from a Younger to Older Age Group

CDC recommends vaccine recipients receive the recommended age-appropriate vaccine product and dosage based on their age on the day of vaccination.

- If a person moves from a younger age group to an older age group during the primary series or between the primary series and receipt of the booster dose(s), they should receive the vaccine product and dosage for the older age group for all subsequent doses.
- FDA emergency use authorization (EUA) allows for different dosing for certain age transitions, which are not considered vaccine administration errors and do not need to be reported to the Vaccine Adverse Event Reporting System (VAERS).

rned from age 4 to age 5 years between dose 1 and dose 2

8 weeks

Dose 3 (Age 5):
0.20 mL (10 mcg) of the product authorized for children ages 5–11 years (orange cap and label border)

rned from age 4 to age 5 years between dose 2 and dose 3

8 weeks

Child turns 5

Dose 3 (Age 5):
0.20 mL (10 mcg) of the product authorized for children ages 5–11 years (orange cap and label border)

ed an error and the primary series is considered complete.
ccine product authorized for children ages 5–11 years

Dose 2: Age 4 or 5

1

Moderna COVID-19 Vaccine
for Children who Transition from a Younger to Older Age Group

CDC recommends vaccine recipients receive the recommended age-appropriate vaccine product and dosage based on their age on the day of vaccination.

- If a person moves from a younger age group to an older age group during the primary series, they should receive the vaccine product and dosage for the older age group for all subsequent doses.
- FDA emergency use authorization (EUA) allows for different dosing for certain age transitions, which are not considered vaccine administration errors and do not need to be reported to the Vaccine Adverse Event Reporting System (VAERS).

**Children who turn from age 5 to age 6 years**

**Recommended:** Children who started a primary series and turned from age 5 to age 6 years before completion of the series should receive:

**Dose 1 (Age 5):**
0.25 mL (25 mcg) of the product authorized for children ages 6 months–5 years (dark blue cap/ magenta label border)

4-8 weeks

Child turns 6

**Dose 2 (Age 6):**
0.50 mL (50 mcg) of the product authorized for children ages 6–11 years (dark blue cap/ purple label border)

**Acceptable:** : If the following dosing occurs, it is NOT considered an error and the primary series is considered complete.

**Either dose may be:**

- 0.25 mL (25 mcg) of the product authorized for children ages 6 months–5 years (dark blue cap/magenta label border), or
- 0.50 mL (50 mcg) of the product authorized for children ages 6–11 years (dark blue cap/purple label border)

**Dose 1: Age 5** OR

4-8 weeks

**Dose 2: Age 6** OR

06/23/2022

1

# Interchangeability

- COVID-19 vaccines are not interchangeable.
- The same mRNA vaccine product should be used for all doses of the primary series.
- In exceptional situations in which the mRNA vaccine product administered for a previous dose(s) of the primary series cannot be determined or is not available, either age-appropriate available mRNA COVID-19 vaccine product may be administered at a minimum interval of 28 days between doses to complete the mRNA COVID-19 primary vaccination series.

# Mixed Series For Children Ages 6 months–4 Years

- Children ages 6 months–4 years who receive different mRNA products for the first 2 doses of an mRNA COVID-19 vaccine series should receive a third dose of either mRNA vaccine 8 weeks after the second dose to complete the 3-dose primary series.

# Mixed Series For Children Ages 6 months–4 Years

- **Scenario 1**:




**Dose 1:**
0.20 mL (3mcg) of the Pfizer-BioNTech product for ages 6 months through 4 years

**Dose 2:**
0.25 mL (25mcg) of the Moderna product for ages 6 months through 5 years

**Dose 3:**
0.20 mL (3mcg) of the Pfizer-BioNTech product for ages 6 months through 4 years
**--or--**
0.25 mL (25mcg) of the Moderna product for ages 6 months through 5 years

# Mixed Series For Children Ages 6 months–4 Years

- **Scenario 1**:


**Dose 1:**
0.25 mL (25mcg) of the Moderna product for ages 6 months through 5 years

**Dose 2:**
0.20 mL (3mcg) of the Pfizer-BioNTech product for ages 6 months through 4 years

**Dose 3:**
0.20 mL (3mcg) of the Pfizer-BioNTech product for ages 6 months through 4 years
**--or--**
0.25 mL (25mcg) of the Moderna product for ages 6 months through 5 years

# Preventing Vaccine Administration Errors

- Clinical guidance for errors: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#appendix-c

- Handout: https://www.cdc.gov/vaccines/hcp/admin/downloads/vaccine-administration-preventing-errors.pdf



YOU CALL THE SHOTS

**Vaccine Administration: Preventing Vaccine Administration Errors**

A vaccine administration error is any preventable event that may cause or lead to inappropriate medication use or patient harm.[1] Vaccine administration errors can have many consequences, including inadequate immunological protection, possible injury to the patient, cost, inconvenience, and reduced confidence in the health care delivery system. Take preventive actions to avoid vaccine administration errors and establish an environment that values reporting and investigating errors as part of risk management and quality improvement.

Vaccine administration errors may be due to causes such as:

- Insufficient staff training
- Distraction
- Changes in recommendations
- Lack of standardized protocols
- Patient misidentification
- Using nonstandard or error-prone abbreviations
- Easily misidentified products (e.g. DTaP, DT, Tdap, Td)

If an error occurs, determine how it occurred and take the appropriate actions to put strategies in place to prevent it from happening in the future. The following table outlines common vaccine administration errors and possible preventive actions you can take to avoid errors.

| Error(s) | Possible Preventive Actions |
|---|---|
| **Wrong vaccine, route, site, or dosage (amount); or improperly prepared.** | Circle important information on the packaging to emphasize the difference between the vaccines. |
| | Include the brand name with the vaccine abbreviation whenever possible (e.g., PCV13 [Prevnar13]) in orders, medical screens, etc. |
| | Separate vaccines into bins or other containers according to type and formulation. Use color-coded identification labels on vaccine storage containers. |
| | Store look-alike vaccines in different areas of the storage unit (e.g., pediatric and adult formulations of the same vaccine on different shelves in the unit). |
| | Do not list vaccines with look-alike names sequentially on computer screens, order forms, or medical records, if possible. |
| | Consider using "name alert" or "look-alike" stickers on packaging and areas where these vaccines are stored. |
| | Consider purchasing products with look-alike packaging from different manufacturers, if possible. |
| | Establish "Do NOT Disturb" or no-interruption areas or times when vaccines are being prepared or administered. |
| | Prepare vaccine for one patient at a time. Once prepared, label the syringe with vaccine name. |
| | Do not administer vaccines prepared by someone else. |
| | Triple-check work before administering a vaccine and ask another staff member to check. |
| | Keep reference materials on recommended sites, routes, and needle lengths for each vaccine used in your facility in the medication preparation area. |
| | Clearly identify diluents if the manufacturer's label could mislead staff into believing the diluent is the vaccine itself. |
| | Integrate vaccine administration training into orientation and other appropriate education requirements. |
| | Provide education when new products are added to inventory or recommendations are updated. |
| | Use standing orders, if appropriate. |

1. National Coordinating Council for Medication Error Reporting and Prevention, https://www.nccmerp.org/about-medication-errors

g Vaccine Administration Errors

ntive Actions

t's identity before administering vaccines.

the importance of avoiding unnecessary distractions or interruptions when staff is accine.

inister vaccines to one patient at a time. If more than one patient needs vaccines clinical encounter (e.g., parent with two children), assign different providers to each le. Alternatively, bring only one patient's vaccines into the treatment area at a time, cine and patient name.

-prone abbreviations to document vaccine administration (e.g., use intranasal route ent the intranasal route—not IN, which is easily confused with IM).

e abbreviations.

earance of look-alike names or generic abbreviations on computer screens, if possible.

e storage and handling training based on manufacturer guidance and/or

so those with the earliest expiration dates are in the front of the storage unit. Use

vaccines/diluents from storage units and areas where viable vaccines are stored.

exposed to improper temperatures and contact the state or local immunization the vaccine manufacturer.

ders, if appropriate.

es to obtain a complete vaccination history using the immunization information vious medical records, and personal vaccination records.

e administration training, including timing and spacing of vaccines, into orientation priate education requirements.

ecially infants, schedule immunization visits after the birthday.

munization schedules for children and adults that staff can quickly reference in clinical cinations may be prescribed and administered.

heets for timing and spacing in your medication preparation area. CDC has vaccine ce for DTaP, Tdap, Hib, PCV13, and polio vaccines to assist health care personnel in catch-up schedule for children.

and patients on how important it is for them to maintain immunization records.

e 11-2, Medication Errors, 2nd ed, by Cohen, Michael. Washington D.C: American Pharmacists Association; 2007.

to report vaccine administration errors to ERS)." To file an electronic report, please see the VAERS website at https://vaers.hhs.gov/reportevent.html

* At this time, COVID-19 vaccination has additional VAERS reporting requirements, including required reporting of vaccine administration errors. Please see https://vaers.hhs.gov/faq.html for more information.

# Interim Clinical Considerations

- Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html

- FAQs for the Interim Clinical Considerations: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/faq.html



# Clinical Resources

- US COVID-19 Vaccine Product Information:

https://www.cdc.gov/vaccines/covid-19/info-by-product/index.html



# CT WiZ/VAMS Update

# CT WiZ Updates

# The Recommender in CT WiZ

# New Immunization Program Webpage *Coming Soon!*

Version 1.0
6/30/2022

# VAMS to CT WiZ Transition

- Effective 7/1/2022, the CT WiZ law was amended mandating all vaccinating providers to report electronically to CT WiZ.
- DPH will help VAMS clinics transition to CT WiZ. Submit a **helpdesk ticket** with your PIN to start the process.
- DPH will schedule a call to review the **transition process** with your clinic.



VAMS CLINIC to CT WiZ TRANSITION CHECKLIST

Clinic Name: _____ PIN: _____ Transition Date: _____

**RESPONSIBILITIES AND EXPECTATIONS**

- ☐ After helpdesk ticket is received with the PIN and expected date of transition, DPH schedules a meeting
- ☐ Determine Clinic's Transition 'End Date' of VAMS.
- ☐ Clinic can use their EHR if onboarded or Direct Data Entry (User Interface-UI) in CT WiZ: (Train on CT WiZ, Move inventory to CT WiZ)
- ☐ UI: Plan/workflow for entering into CT WiZ. Click here for the paper vaccination administration form. This can be used to capture information to later be entered into the CT WiZ user interface.

**CLOSE DOWN VAMS SCHEDULE**

- ☐ Review Appointment Schedule relative to VAMS 'End Date'.
- ☐ Enter VAMS End Date in the Clinic Setup screen.
- ☐ Uncheck the 'Available for Scheduling' checkbox to prevent new appointments.
- ☐ Change Treatment Station End Dates to match VAMS 'End Date'.
- ☐ Add Clinic Absences to prevent new appointment slots.
- ☐ **Communicate with recipients about cancellation of appointments in VAMS**, as they may receive a cancellation notification or reminder email. ***Include a note when you cancel appointments.** See VAMS Clinic Admin User Manual (section "Send Messages to Recipients with Scheduled or Completed Appointments")

**APPOINTMENT SCHEDULING**

- ☐ Communicate with recipients on how appointments will be scheduled (ex. website, call center, scheduling system) and not in VAMS.
- ☐ Vaccines.gov will enable the public to see your clinic's available COVID-19 vaccines (and flu if you choose) if you wish to publicly display your clinic. Visit: Providers Resources on how to publicly display your clinic (optional) and report daily inventory counts (required).

**RECONCILE ON-HAND INVENTORY**

- ☐ Document all doses administered in VAMS (past and current).
- ☐ Review inventory in all clinic types in VAMS and compare to your physical on-hand inventory.
- ☐ Pull all final reports from VAMS that you may need (billing, vaccine administration, etc.).
  *Note: VAMS data administered in CT is sent to CT WiZ. CT WiZ has the consolidated record.*

**CT WiZ READY**

- ☐ Determine users in CT WiZ and roles and ensure all staff have appropriate access.
- ☐ Review CT WiZ Training webpage and **Schedule CT WiZ Training** with CVP Team.
- ☐ Prepare on-hand inventory to "transfer" from VAMS to CT WiZ.
- ☐ Notify DPH you are ready to deactivate your Clinic in VAMS.

Finally, CT DPH will email you a confirmation when you complete the transition, and you will stop using VAMS and start using CT WiZ for your administration and inventory functions. You will only enter immunizations into your EHR if onboarded or directly in the UI in CT WiZ from your transition date.

12/1/2021

# COVID-19 Vaccine Updates

- CT WiZ has been updated with the new young pediatric COVID-19 vaccines:
  - Vaccines_Supplied_By_CT_CVP_62422.pdf

Please ensure you enter the correct COVID-19 vaccines.

**STATE OF CONNECTICUT**

DEPARTMENT OF PUBLIC HEALTH

IMMUNIZATION PROGRAM

Vaccines supplied by the Connecticut Vaccine Program as of June 24, 2022

| Vaccine | Brand Name and Packaging | NDC | Manufacturer | CVX | CT WiZ Drop Down Selection |
|---|---|---|---|---|---|
| COVID Tris-Suc (PFR 6mo-4y) | PFR COVID Tris-sucrose (10 x 10(0.2mL/dose) MDV) | 59267-0078-04 | Pfizer, Inc. | 219 | COVID Tris-Suc (PFR 6mo-4y) |
| COVID Tris-Suc (PFR 12+) | PFR COVID Tris-sucrose (10 x 6 (0.3mL/dose) MDV) | 59267-1025-04 | Pfizer, Inc. | 217 | COVID Tris-Suc (PFR 12+) |
| COVID Tris-Suc (PFR 16+) | Pfizer Comirnaty COVID-19 (10 x 2.0mL MDV) | 00069-2025-10 | Pfizer, Inc. | 217 | COVID Tris-Suc (PFR 12+) |
| COVID Tris-Suc (PFR 5-12) | Pfizer COVID-19 (.2mL/dose) MDV) | 59267-1055-04 | Pfizer, Inc. | 218 | COVID Tris-Suc (PFR 5-12) |
| COVID-19 (MOD) 6mo - <6yr | Moderna COVID-19 Ped 6mo - 6yr (10 x 2.5mL Vials) | 80777-0279-99 | Moderna | 228 | COVID-19 (MOD) 6mo - <6yr |
| COVID-19 (MOD) 6-11, Booster | Moderna COVID-19 6-11yr (10 x 2.5mL Vials) | 80777-0275-99 | Moderna | 221 | COVID-19 (MOD) Booster |
| COVID-19 mRNA (MOD) | Moderna COVID-19 (10 x 10 dose 5.0 mL MDV) | 80777-0273-99 | Moderna | 207 | COVID-19 mRNA (MOD) |
| COVID-19 Vector-NR (JSN) | Janssen COVID-19 (10 x 5 dose 5.0 mL MDV) | 59676-0580-15 | Janssen | 212 | COVID-19 Vector-NR (JSN) |
| DTaP | Infanrix (0.5 mL x 10 syr) | 58160-0810-52 | GlaxoSmithKline | 20 | DTaP |
| DTaP (Daptacel) | Daptacel (0.5 mL x 10 vials) | 49281-0286-10 | Sanofi Pasteur | 106 | DTaP (Daptacel) |
| DTaP-HepB-IPV | Pediarix (0.5 mL x 10 syr | 58160-0811-52 | GlaxoSmithKline | 110 | DTaP-HepB-IPV |
| DTaP-Hib-IPV (Pentac | PENTACEL (SDV; 5 PACK) | 49281-0511-05 | Sanofi Pasteur | 120 | DTaP-Hib-IPV (Pentac |
| DTaP-IPV | Kinrix (0.5 mL x 10 syr) | 58160-0812-52 | GlaxoSmithKline | 130 | DTaP-IPV |
| DTaP-IPV | Quadracel 10 pack | 49281-0564-15 | Sanofi Pasteur | 130 | DTaP-IPV |
| DTaP-IPV-Hib-Hep B | Vaxelis (10 x 0.5mL Syringes) | 63361-0243-15 | MSP Vaccine Company | 146 | DTaP-IPV-Hib-Hep B |
| Flu MDCK Quad P-Free Inj | Flucelvax Quad 2021-2022 (10 x 0.5mL Syringes) | 70461-0321-03 | Seqirus | 171 | Flu MDCK Quad P-Free Inj |
| Hep A, adult | Havrix (1 mL x 10 syr) | 58160-0826-52 | GlaxoSmithKline | 52 | Hep A, adult |
| Hep A, ped/adol, 2D | Havrix (0.5 mL x 10 syr) | 58160-0825-52 | GlaxoSmithKline | 83 | Hep A, ped/adol, 2D |
| Hep A, ped/adol, 2D | Vaqta (0.5 mL x 10 syr) | 00006-4095-02 | Merck & Co, Inc. | 83 | Hep A, ped/adol, 2D |
| Hep B, adult | Heplisav-B | 43528-0003-05 | Dynavax | 43 | Hep B, adult |
| Hep B, ped/adol | Engerix B (0.5 mL x 10 syr) | 58160-0820-52 | GlaxoSmithKline | 08 | Hep B, ped/adol |
| Hep B, ped/adol | Recombivax (0.5 mL x 10 vials) | 00006-4981-00 | Merck & Co, Inc. | 08 | Hep B, ped/adol |

To access this document from the CVP webpage, visit: https://portal.ct.gov/DPH/Immunizations/CVP---Information-for-Providers under Blue Folder.

# CT WiZ Recommender

- When there is a new vaccine recommendation or a change in the vaccine schedule, it requires the **CT WiZ Recommender to be updated in a new CT WiZ release.**
  - If you see a valid dose with an ! (invalid), when the Recommender is updated, the ! will disappear and the dose will display as valid.
- Tip: Print the Full immunization record until the Recommender is updated. (The COVID-19 only record only displays valid doses.)

# New Immunization Program Webpage!

# Question and Answers

To ask a question, please raise your hand using the hand icon on your screen, type your question in the chat box or if you are on the phone press *6 to unmute yourself.

If you have additional questions after the meeting, please feel free to email them to DPH.Immunizations@ct.gov

You can fill out a help desk ticket by visiting https://dph-cthelpdesk.ct.gov/Ticket